齐拉西酮治疗女性精神分裂症的对照研究  

Comparison study of ziprasidone in female patients with schizophrenia

作　　者：夏仲[1] 汪正华[1] 宋传福[1] 

机构地区：[1]安徽省芜湖市第四人民医院,241002

出　　处：《四川精神卫生》2012年第1期29-31,共3页Sichuan Mental Health

摘　　要：目的比较齐拉西酮与利培酮治疗女性精神分裂症的疗效和安全性。方法将60例女性精神分裂症随机分为二组,分别给予齐拉西酮和利培酮治疗8周。于治疗前及治疗第4、8周末采用阳性与阴性症状量表(PANSS)评定疗效,以治疗时出现的症状量表(TESS)评定不良反应。结果在治疗第8周末,两组PAN-SS评分较入组时均有显著降低(P<0.01);齐拉西酮组有效率为90.0%,显效率为66.7%;利培酮组有效率为93.3%,显效率为73.3%,两组无显著性差异(P>0.05)。齐拉西酮组较利培酮组更少引起锥体外系反应、体重增加及月经改变(P<0.05或P<0.01)。结论齐拉西酮是一种安全有效的抗精神病药物,更适合于女性精神分裂症患者使用。Objective To compare the curative effect and by-reaction in female schizophrenia patients treated by ziprasidone and risperidone.Method 60 female schizophrenia patient swere randomly divided into ziprasidone group and risperidone group for 8 weeks.The therapeutic effects were assessed by postive and negative symptom scale（PANSS）,and the adverse effects were evaluated by treatment emergent symptom scale（TESS）after the treatment of 4,8 weekend.Results The PANSS scores significantly decreased compared with the baseline sores in both groups after 8 weekend（P0.01）;the marked improvement rate was 67.7% and the total clinical effective rate was 90.0% in ziprasidone group while 73.3% and 93.3% in risperidone group,there were not significant differences between two groups（P0.05）.The incidence of extrapyramidal symptoms,weight gain,menstrual changes were significantly lower in the ziprasidone group than those in the risperidone group（P0.05 or P0.01）.Conclusion Ziprasidone is a safe and effective antipsychotic drugs,in the treatment of female patiens with schizophrenia.

关 键 词：精神分裂症 齐拉西酮 利培酮 女性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]